Listed

BriaCell Therapeutics Corp.: Form 10-Q for the period ended Jan 31, 2023

Filed with the SEC on Mar 16, 2023 and accepted by EDGAR at Mar 15, 2023, 18:00 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-01-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2022-11-01 to 2023-01-31$3.1mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2022-08-01 to 2023-01-31$6.3mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2022-11-01 to 2023-01-31−$4.5mus-gaap:OperatingIncomeLoss
Operating income6 months2022-08-01 to 2023-01-31−$9.9mus-gaap:OperatingIncomeLoss
Net income3 months2022-11-01 to 2023-01-31−$11.9mus-gaap:NetIncomeLoss
Net income6 months2022-08-01 to 2023-01-31−$13.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2022-11-01 to 2023-01-31−$0.77us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2022-08-01 to 2023-01-31−$0.84us-gaap:EarningsPerShareDiluted
Basic EPS3 months2022-11-01 to 2023-01-31−$0.77us-gaap:EarningsPerShareBasic
Basic EPS6 months2022-08-01 to 2023-01-31−$0.84us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2022-11-01 to 2023-01-3115,518,018 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2022-08-01 to 2023-01-3115,518,018 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2022-08-01 to 2023-01-31−$7.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2023-01-31$33.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-01-31$33.9mus-gaap:AssetsCurrent
Total assetsAt period end2023-01-31$34.2mus-gaap:Assets
Current liabilitiesAt period end2023-01-31$670.4kus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2023-01-31−$1.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-23-007796. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.